The nurse is caring for a patient who has multiple sclerosis. The patient is experiencing an acute attack. Which drug does the nurse anticipate the provider will order?
Interferon-B (IFN-B)
Mitoxantrone
Glatiramer acetate (Copaxone)
Methylprednisolone (Solu-Medrol)
The Correct Answer is D
A) Interferon-B (IFN-B): Interferon-beta is a disease-modifying therapy (DMT) used for multiple sclerosis (MS) to reduce the frequency and severity of attacks and slow disease progression. However, it is not typically used during an acute exacerbation of MS. It is more commonly prescribed for long-term management of the disease.
B) Mitoxantrone: Mitoxantrone is an immunosuppressive agent that is used as a disease-modifying therapy for patients with more aggressive forms of MS. While it can be helpful in reducing the frequency of attacks, it is not the first-line treatment during an acute relapse. Mitoxantrone is often considered for long-term use when other therapies are not effective.
C) Glatiramer acetate (Copaxone): Glatiramer acetate is another disease-modifying therapy for MS. It works by altering the immune response to protect the myelin sheath. Like interferon-beta, it is used for long-term management, not for acute attacks. It is not typically used during an exacerbation of MS.
D) Methylprednisolone (Solu-Medrol): Methylprednisolone, a corticosteroid, is the standard treatment for acute exacerbations of multiple sclerosis. It works by reducing inflammation, which helps to decrease the severity of symptoms during an MS relapse. The nurse would anticipate this drug being prescribed to manage the acute inflammatory episode and speed recovery from the attack. This medication is often administered intravenously in high doses and then tapered as the patient stabilizes.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is D
Explanation
A) Increase in mental acuity: Beta-adrenergic blockers (beta-blockers) do not directly affect mental acuity. In fact, some beta-blockers may cause side effects like fatigue or drowsiness, which can affect mental sharpness. Beta-blockers primarily focus on cardiovascular effects, not cognitive function, making this an unlikely therapeutic goal for their use.
B) Slowing of gastrointestinal motility: Beta-blockers can reduce sympathetic nervous system activity, which may indirectly affect the gastrointestinal system. However, slowing gastrointestinal motility is not a primary therapeutic goal of beta-blocker therapy. The main action of beta-blockers is in the cardiovascular system, not in regulating GI function.
C) Decreased production in gastric acid: Beta-blockers do not significantly reduce gastric acid production. Medications such as proton pump inhibitors or H2 blockers are typically used for managing gastric acid production or reflux. Beta-blockers focus on reducing the workload of the heart and controlling blood pressure, not on acid secretion.
D) Reduction in the heart rate and blood pressure: The primary therapeutic effect of beta-blockers is the reduction of heart rate (negative chronotropic effect) and blood pressure (due to reduced cardiac output and inhibition of the sympathetic nervous system). This is especially beneficial for managing conditions like hypertension, heart failure, and arrhythmias. It is the most likely goal of beta-blocker therapy prescribed by the provider.
Correct Answer is A
Explanation
A) Increased intraocular pressure: Sympathomimetic drugs stimulate the sympathetic nervous system and promote "fight or flight" responses, often resulting in vasoconstriction and other effects. Some sympathomimetics, especially those that affect alpha-adrenergic receptors, can lead to increased intraocular pressure, which is a concern in conditions like glaucoma.
B) Decreased blood pressure: Sympathomimetic drugs generally increase blood pressure by stimulating alpha and beta receptors that cause vasoconstriction and increased heart rate. In contrast, drugs that would decrease blood pressure are usually parasympathomimetics or other agents designed to block sympathetic responses.
C) Decreased heart rate: Sympathomimetic drugs typically increase heart rate by stimulating beta-1 adrenergic receptors in the heart. These drugs are used in situations requiring increased cardiac output or to counteract bradycardia. Decreased heart rate would typically occur with parasympathomimetic drugs or medications that block sympathetic activity (e.g., beta blockers).
D) Increased respiration: Sympathomimetic drugs can increase respiratory rate by promoting bronchodilation through beta-2 adrenergic receptor activation in the lungs. However, "increased respiration" as a general effect is not as specific or consistent as the other cardiovascular and ocular effects of these drugs. The primary and most prominent physiological change would be related to the cardiovascular effects.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.
